Literature DB >> 20960451

Proteomic characterization of Her2/neu-overexpressing breast cancer cells.

Hexin Chen1, Genaro Pimienta, Yiben Gu, Xu Sun, Jianjun Hu, Min-Sik Kim, Raghothama Chaerkady, Marjan Gucek, Robert N Cole, Saraswati Sukumar, Akhilesh Pandey.   

Abstract

The receptor tyrosine kinase HER2 is an oncogene amplified in invasive breast cancer and its overexpression in mammary epithelial cell lines is a strong determinant of a tumorigenic phenotype. Accordingly, HER2-overexpressing mammary tumors are commonly indicative of a poor prognosis in patients. Several quantitative proteomic studies have employed two-dimensional gel electrophoresis in combination with MS/MS, which provides only limited information about the molecular mechanisms underlying HER2/neu signaling. In the present study, we used a SILAC-based approach to compare the proteomic profile of normal breast epithelial cells with that of Her2/neu-overexpressing mammary epithelial cells, isolated from primary mammary tumors arising in mouse mammary tumor virus-Her2/neu transgenic mice. We identified 23 proteins with relevant annotated functions in breast cancer, showing a substantial differential expression. This included overexpression of creatine kinase, retinol-binding protein 1, thymosin 4 and tumor protein D52, which correlated with the tumorigenic phenotype of Her2-overexpressing cells. The differential expression pattern of two genes, gelsolin and retinol binding protein 1, was further validated in normal and tumor tissues. Finally, an in silico analysis of published cancer microarray data sets revealed a 23-gene signature, which can be used to predict the probability of metastasis-free survival in breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20960451      PMCID: PMC4327899          DOI: 10.1002/pmic.201000297

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  45 in total

Review 1.  EGF-ERBB signalling: towards the systems level.

Authors:  Ami Citri; Yosef Yarden
Journal:  Nat Rev Mol Cell Biol       Date:  2006-07       Impact factor: 94.444

2.  Aldehyde dehydrogenase 1A1 and gelsolin identified as novel invasion-modulating factors in conditioned medium of pancreatic cancer cells.

Authors:  Naomi Walsh; Paul Dowling; Norma O'Donovan; Michael Henry; Paula Meleady; Martin Clynes
Journal:  J Proteomics       Date:  2008-09-25       Impact factor: 4.044

3.  Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer.

Authors:  Paul J Adam; Robert Boyd; Kerry L Tyson; Graham C Fletcher; Alasdair Stamps; Lindsey Hudson; Helen R Poyser; Nick Redpath; Matthew Griffiths; Graham Steers; Adrian L Harris; Sonal Patel; Joanne Berry; Julie A Loader; R Reid Townsend; Laurent Daviet; Pierre Legrain; Raj Parekh; Jonathan A Terrett
Journal:  J Biol Chem       Date:  2002-12-10       Impact factor: 5.157

4.  Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.

Authors:  Annalisa Astolfi; Lorena Landuzzi; Giordano Nicoletti; Carla De Giovanni; Stefania Croci; Arianna Palladini; Silvano Ferrini; Manuela Iezzi; Piero Musiani; Federica Cavallo; Guido Forni; Patrizia Nanni; Pier-Luigi Lollini
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

5.  Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.

Authors:  Huayi Huang; Jeff Groth; Khalid Sossey-Alaoui; Lesleyann Hawthorn; Stephanie Beall; Joseph Geradts
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

6.  Proteome profile of the MCF7 cancer cell line: a mass spectrometric evaluation.

Authors:  Hetal A Sarvaiya; Jung H Yoon; Iulia M Lazar
Journal:  Rapid Commun Mass Spectrom       Date:  2006       Impact factor: 2.419

7.  The Ki67+ proliferation index correlates with increased cellular retinol-binding protein-1 and the coordinated loss of plakophilin-1 and desmoplakin during progression of cervical squamous lesions.

Authors:  A Schmitt-Graeff; A Koeninger; M Olschewski; S Haxelmans; R Nitschke; M-L Bochaton-Piallat; B Lifschitz-Mercer; G Gabbiani; L Langbein; B Czernobilsky
Journal:  Histopathology       Date:  2007-07       Impact factor: 5.087

8.  Hoxb7 inhibits transgenic HER-2/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis.

Authors:  Hexin Chen; Ji Shin Lee; Xiaohui Liang; Huiping Zhang; Tao Zhu; Zhe Zhang; M Evangeline Taylor; Cynthia Zahnow; Lionel Feigenbaum; Alan Rein; Saraswati Sukumar
Journal:  Cancer Res       Date:  2008-05-07       Impact factor: 12.701

9.  Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.

Authors:  Priti S Hegde; David Rusnak; Melissa Bertiaux; Krystal Alligood; Jay Strum; Robert Gagnon; Tona M Gilmer
Journal:  Mol Cancer Ther       Date:  2007-05       Impact factor: 6.261

10.  Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping.

Authors:  Keli Ou; Kun Yu; Djohan Kesuma; Michelle Hooi; Ning Huang; Wei Chen; Suet Ying Lee; Xin Pei Goh; Lay Keng Tan; Jia Liu; Sou Yen Soon; Suhaimi Bin Abdul Rashid; Thomas C Putti; Hiroyuki Jikuya; Tetsuo Ichikawa; Osamu Nishimura; Manuel Salto-Tellez; Patrick Tan
Journal:  J Proteome Res       Date:  2008-03-05       Impact factor: 4.466

View more
  12 in total

Review 1.  Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?

Authors:  Jennifer A Byrne; Sarah Frost; Yuyan Chen; Robert K Bright
Journal:  Tumour Biol       Date:  2014-05-06

2.  Determination of the Proteomic Response to Lapatinib Treatment using a comprehensive and reproducible ion-current-based proteomics strategy.

Authors:  Kathleen O'Connell; Jun Li; Frank Engler; Kim Hennessy; Fiona O'Neill; Robert M Straubinger; Jun Qu; Robert O'Connor
Journal:  J Proteom Genom Res       Date:  2013-09-08

3.  HOXB7 promotes malignant progression by activating the TGFβ signaling pathway.

Authors:  Shou Liu; Kideok Jin; Yvonne Hui; Jie Fu; Chunfa Jie; Sheng Feng; David Reisman; Qian Wang; Daping Fan; Saraswati Sukumar; Hexin Chen
Journal:  Cancer Res       Date:  2014-12-26       Impact factor: 12.701

4.  Moonlight human ribosomal protein L13a downregulation is associated with p53 and HER2/neu expression in breast cancer.

Authors:  Ghader Molavi; Nasser Samadi; Shahriar Hashemzadeh; Monireh Halimi; Elaheh Zadeh Hosseingholi
Journal:  J Appl Biomed       Date:  2020-06-17       Impact factor: 1.797

5.  Tumor protein D54 is a negative regulator of extracellular matrix-dependent migration and attachment in oral squamous cell carcinoma-derived cell lines.

Authors:  Yoshiki Mukudai; Seiji Kondo; Atsushi Fujita; Yasuto Yoshihama; Tatsuo Shirota; Satoru Shintani
Journal:  Cell Oncol (Dordr)       Date:  2013-03-26       Impact factor: 6.730

6.  CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.

Authors:  P-K Lo; D Kanojia; X Liu; U P Singh; F G Berger; Q Wang; H Chen
Journal:  Oncogene       Date:  2011-09-26       Impact factor: 9.867

7.  Nonlinear growth kinetics of breast cancer stem cells: implications for cancer stem cell targeted therapy.

Authors:  Xinfeng Liu; Sara Johnson; Shou Liu; Deepak Kanojia; Wei Yue; Udai P Singh; Udai Singn; Qian Wang; Qi Wang; Qing Nie; Hexin Chen
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

8.  AHNAK2 is a potential prognostic biomarker in patients with PDAC.

Authors:  Di Lu; Junxiong Wang; Xiaoyan Shi; Bing Yue; Jianyu Hao
Journal:  Oncotarget       Date:  2017-05-09

9.  Tumor Proteins D52 and D54 Have Opposite Effects on the Terminal Differentiation of Chondrocytes.

Authors:  Chihiro Ito; Yoshiki Mukudai; Masakatsu Itose; Kosuke Kato; Hiromi Motohashi; Toshikazu Shimane; Seiji Kondo; Tatsuo Shirota
Journal:  Biomed Res Int       Date:  2017-07-17       Impact factor: 3.411

10.  Unravelling Structure, Localization, and Genetic Crosstalk of KLF3 in Human Breast Cancer.

Authors:  Khushbukhat Khan; Sadia Safi; Asma Abbas; Yasmin Badshah; Erum Dilshad; Mehak Rafiq; Kainat Zahra; Maria Shabbir
Journal:  Biomed Res Int       Date:  2020-12-28       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.